Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia-Reference-Cited by-同舟云学术

Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia

Published:2022-06 Issue:3 Volume:11 Page:
ISSN:2045-1393
Container-title:International Journal of Hematologic Oncology
language:en
Short-container-title:International Journal of Hematologic Oncology

Author:

Saydam Guray¹^ORCID,Unal Ali²^ORCID,Haznedaroglu Ibrahim Celalettin³^ORCID,Hacihanifioglu Abdullah⁴^ORCID,Mehtap Ozgur⁴^ORCID,Kurtoglu Erdal⁵^ORCID,Gocer Mesut⁵^ORCID,Turgut Mehmet⁶^ORCID,Kelkitli Engin⁶^ORCID,Atay Memis Hilmi⁶^ORCID,Guler Nil⁷^ORCID,Koluman Basak Unver⁷^ORCID,Sonmez Mehmet⁸^ORCID,Erkut Nergiz⁸^ORCID,Kaya Emin⁹^ORCID,Kuku Irfan⁹^ORCID,Erkurt Mehmet Ali⁹^ORCID,Ozet Gulsum¹⁰¹¹^ORCID,Ceran Funda¹⁰^ORCID,Sahin Fahri¹^ORCID,Soyer Nur¹^ORCID,Nalcaci Meliha¹²^ORCID,Yilmaz Mehmet¹³^ORCID,Bozkurt Sirac¹⁴^ORCID,Aver Birkan¹⁴^ORCID,Ozdengulsun Begum¹⁴^ORCID,Ozbilgili Egemen¹⁴^ORCID,Ilhan Osman¹⁵^ORCID

Affiliation:

1. Department of Internal Diseases, Division of Hematology, Ege University Medical Faculty Hospital, Izmir, 35100, Turkey

2. Department of Internal Diseases, Division of Hematology, Erciyes University Faculty of Medicine, Kayseri, 38030, Turkey

3. Department of Internal Diseases, Division of Hematology, Hacettepe University Faculty of Medicine, Ankara, 06230, Turkey

4. Department of Internal Diseases, Division of Hematology, Kocaeli University Faculty of Medicine, Izmit, 41001, Turkey

5. Department of Internal Diseases, Division of Hematology, University of Health Sciences, Antalya Training & Research Hospital, Antalya, 07100, Turkey

6. Department of Internal Diseases, Division of Hematology, Ondokuz Mayis University Faculty of Medicine, Samsun, 55139, Turkey

7. Department of Internal Diseases, Pamukkale University Faculty of Medicine, Denizli, 20160, Turkey

8. Department of Internal Diseases, Division of Hematology, Karadeniz Technical University Faculty of Medicine, Trabzon, 61080, Turkey

9. Department of Internal Diseases, Division of Hematology, Inonu University Faculty of Medicine, Malatya, 44280, Turkey

10. Department of Hematology, Ankara City Hospital, Ankara, 06800, Turkey

11. Department of Internal Diseases, Ankara Yıldırım Beyazit University Faculty of Medicine, Ankara, 06800, Turkey

12. Department of Internal Diseases, Istanbul University Istanbul Faculty of Medicine, Istanbul, 34093, Turkey

13. Department of Internal Diseases, Division of Hematology, SANKO University Faculty of Medicine, Gaziantep, 27090, Turkey

14. Department of Medical Oncology, Pfizer Pharmaceuticals, Istanbul, 34394, Turkey

15. Department of Internal Diseases, Division of Hematology, Ankara University Faculty of Medicine, Ankara, 06230, Turkey

Abstract

Aim: This study aimed to identify patient characteristics, treatment patterns and outcomes and to evaluate the effects of presence of comorbidities at diagnosis in chronic phase (CP)-chronic myeloid leukemia (CML) patients in Turkey. Materials & methods: Hospital records between 2005 and 2018 were retrospectively reviewed. Results: Of 861 CP-CML patients included, 31% had at least one comorbidity at diagnosis. Sex, cardiovascular disease status at diagnosis and molecular (at least major) and cytogenetic (partial and complete) responses were the independent predictors of survival. Conclusion: The response rates of CP-CML patients to the tyrosine kinase inhibitors were satisfactory. In addition to tolerability and side effect profiles of drugs, comorbidity status of patients should also be considered in treatment choice in CML patients.

Funder

Pfizer

Publisher

Future Medicine Ltd

Subject

Pharmacology (medical),Oncology,Hematology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/ijh-2021-0008

Reference47 articles.

1. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management

2. Current approach to the treatment of chronic myeloid leukaemia

3. The Cure of Chronic Myeloid Leukemia: Are We There Yet?

4. Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician’s perspective